Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-07-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/17562872211029784 |
| _version_ | 1818437710100037632 |
|---|---|
| author | Giandomenico Roviello Sebastiano Buti Carlo Cattrini Alessia Mennitto Carlo Messina Chiara Airoldi Gianmarco Vannini Melissa Bersanelli |
| author_facet | Giandomenico Roviello Sebastiano Buti Carlo Cattrini Alessia Mennitto Carlo Messina Chiara Airoldi Gianmarco Vannini Melissa Bersanelli |
| author_sort | Giandomenico Roviello |
| collection | DOAJ |
| first_indexed | 2024-12-14T17:29:00Z |
| format | Article |
| id | doaj.art-188809f92a4b473e87c21baf2b6567bc |
| institution | Directory Open Access Journal |
| issn | 1756-2880 |
| language | English |
| last_indexed | 2024-12-14T17:29:00Z |
| publishDate | 2021-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Urology |
| spelling | doaj.art-188809f92a4b473e87c21baf2b6567bc2022-12-21T22:53:09ZengSAGE PublishingTherapeutic Advances in Urology1756-28802021-07-011310.1177/17562872211029784Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?Giandomenico RovielloSebastiano ButiCarlo CattriniAlessia MennittoCarlo MessinaChiara AiroldiGianmarco VanniniMelissa Bersanellihttps://doi.org/10.1177/17562872211029784 |
| spellingShingle | Giandomenico Roviello Sebastiano Buti Carlo Cattrini Alessia Mennitto Carlo Messina Chiara Airoldi Gianmarco Vannini Melissa Bersanelli Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? Therapeutic Advances in Urology |
| title | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_full | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_fullStr | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_full_unstemmed | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_short | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_sort | antiangiogenic tyrosine kinase inhibitors and immunotherapy as first line treatment for metastatic renal cell carcinoma is there an increased risk of hypothyroidism |
| url | https://doi.org/10.1177/17562872211029784 |
| work_keys_str_mv | AT giandomenicoroviello antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT sebastianobuti antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT carlocattrini antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT alessiamennitto antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT carlomessina antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT chiaraairoldi antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT gianmarcovannini antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT melissabersanelli antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism |